An investigational, one-time gene therapy appears to slow the progression of Huntington disease (HD), results of a new phase 1/2 trial suggest. A press release issued by uniQure, the drug's ...
This important manuscript presents a novel application of the SANDI (Soma and Neurite Density Imaging) model to study microstructural alterations in the basal ganglia of individuals with Huntington's ...
Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review ...
22 Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, ...
Poststroke cognitive impairment can significantly impact functional outcomes and quality of life. While comprehensive neuropsychological evaluations are valuable in characterizing this impairment, ...
Credit: Getty Images In an interim analysis of ENLIGHTEN, researchers described changes in cognitive function over 1 year in patients with MS. For the Symbol Digit Modalities Test, clinically ...
In a recent study, beta blockers appeared to significantly lower both the annualized risk for conversion from presymptomatic to symptomatic Huntington’s disease (HD) and the rate of worsening among ...
Sage Therapeutics announced disppointing top-line results from the mid-stage study on dalzanemdor (SAGE-718). The phase II DIMENSION Study was a 12-week, double-blind, placebo-controlled study to ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 clinical trial of dalzanemdor in those with cognitive impairment associated with Huntington’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback